Blurbs

BTIG Remains a Buy on Vicarious Surgical (RBOT)

In a report released yesterday, Ryan Zimmerman from BTIG maintained a Buy rating on Vicarious Surgical (RBOTResearch Report), with a price target of $7.00. The company’s shares closed yesterday at $4.43.

According to TipRanks, Zimmerman is a 5-star analyst with an average return of 9.2% and a 47.60% success rate. Zimmerman covers the Healthcare sector, focusing on stocks such as Vericel, Penumbra, and OrthoPediatrics.

Vicarious Surgical has an analyst consensus of Moderate Buy, with a price target consensus of $6.00.

See the top stocks recommended by analysts >>

RBOT market cap is currently $543.2M and has a P/E ratio of (16.50).

Based on the recent corporate insider activity of 86 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of RBOT in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

D8 Holdings Corp is a blank check company.

Read More on RBOT:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More
Videos
Videos

Latest News Feed